Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 12/20 | 0.69 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.57 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123158 | 0.89 | GPR132 (0.77) | GPR132SMPD1MAOBCMKLR2CMKLR1 | |
| SCHEMBL1122705 | 0.88 | GPR132 (0.76) | GPR132SMPD1CMKLR2CMKLR1GPR139 | |
| SCHEMBL1122743 | 0.88 | GPR132 (0.76) | GPR132SMPD1CMKLR2CMKLR1GPR139 | |
| SCHEMBL1123028 | 0.85 | GPR132 (0.71) | GPR132SMPD1CMKLR2CMKLR1 | |
| SCHEMBL13702183 | 0.84 | GPR132 (0.73) | GPR132SMPD1MAOBNR4A2MEN1 | |
| SCHEMBL1123388 | 0.83 | GPR132 (0.64) | GPR132SMPD1MAOBNR4A2MEN1 | |
| SCHEMBL27658958 | 0.83 | GPR132 (0.64) | GPR132SMPD1MAOBNR4A2MEN1 | |
| SCHEMBL1122747 | 0.82 | GPR132 (0.67) | GPR132SMPD1CMKLR2CMKLR1 | |
| SCHEMBL1123498 | 0.82 | GPR132 (0.63) | GPR132SMPD1MAOBNR4A2MEN1 | |
| SCHEMBL1122813 | 0.82 | GPR132 (0.66) | GPR132SMPD1CMKLR2CMKLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1802583-A1 | HETEROCYCLIC CARBONYL COMPOUNDS | Merck Patent GmbH (DE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006045350-A1 | HETEROCYCLIC CARBONYL COMPOUNDS | MERCK PATENT GMBH (DE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | SGK1, SGK2, SGK3 | GPR132 1885/4885SMPD1 4464/4885MAOB 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.